Besides, SCFAs strengthen the intestinal barrier and reduce LPS-induced endotoxemia by inhibiting inflammatory pathways like NF-κB, suppressing pro-inflammatory cytokines (e.g., TNF-α, IL-1β), and increasing the expression of tight junction proteins (33). The gene discussed is NFKB1; the disease is serum lipopolysaccharide activity.